Short Communication

Frequency and predictors of compliance among patients taking antihypertensive medicines

Ekta Mutneja a, Rakesh Yadav b, Aparajit Ballav Dey c, Pooja Gupta a, *

a Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India
b Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India
c Department of Geriatric Medicine, All India Institute of Medical Sciences, New Delhi, India

ARTICLE INFO

Article history:
Received 5 June 2019
Accepted 28 March 2020
Available online 13 April 2020

Keywords:
Compliance
Hill bone high blood pressure compliance scale
Hypertension
India
Internal consistency
Predictors

ABSTRACT

Introduction: Medication compliance, an important aspect in the treatment of chronic disease research, is often assessed using pill count method. The patient perception is usually not addressed objectively. The present study was conducted to assess patient cognizance, prevalence and predictors of compliance towards antihypertensive therapy in Indian patients.

Methods: Adult patients taking antihypertensive medicines were included from the cardiology and geriatric OPDs of a tertiary care hospital in India. Socio-demographic data and disease awareness information was collected. Hill-Bone high blood pressure compliance scale was administered for compliance score.

Results: For the 452 participants, mean age was 54.6 ± 13.7 years with approximate 2:1 ratio of males to females. Cronbach’s alpha value of 0.7 for Hill Bone compliance scale showed good internal consistency. More than 80% participants had a score of ≥80%, showing good compliance among Indian patients. Factors that were significantly associated with uncontrolled blood pressure with correlation analysis were age, gender and awareness regarding disease.

Conclusion: The study suggests that Hill-Bone high blood pressure compliance scale may be useful for assessing compliance in Indian population. An age appropriate intervention for continued compliance should be considered to improve compliance and hence, reduce long term sequelae of hypertension. © 2020 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Hypertension itself is asymptomatic but it is the largest risk factor for cardiovascular morbidity and mortality. The absence of a curative treatment implies life style changes and lifelong antihypertensive therapy. This makes treatment difficult in terms of compliance as the perceived benefits are few for a lay person with poor knowledge of the disease. Studies suggest a cause effect relationship between unsatisfactory blood pressure control and lack of compliance, thereby increasing the risk of cardiovascular complications. Despite the importance of compliance, there is no universal tool to appropriately assess it across population. Many investigators have used de novo questionnaires which are neither hypertension specific nor validated. Hill bone high blood pressure compliance scale on the other hand is a questionnaire specific for hypertension which is validated in some ethnicities although not in the Indian population.

Compliance is further affected by factors such as disease knowledge, importance of treatment, patient education, financial status and adverse drug reactions. These factors tend to vary with time and region and are further affected by the socio-cultural milieu and demographic shifts. Therefore, it is important to study compliance in a given population, using a validated questionnaire that allows comparison over time, within the population and outside. Hence, the present study was designed to determine the extent of treatment compliance and predictors thereof using Hillbone high blood pressure compliance scale among Indian patients taking antihypertensive medicines.

2. Methods

This was an observational cross sectional study, approved by Institute Ethics Committee (IESC/T-175/15). The participants were

https://doi.org/10.1016/j.ihj.2020.03.008
0019-4832/© 2020 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
enrolled from a large tertiary care hospital that receives patients from different state, culture and socioeconomic status. Participants of age ≥18 years, of either gender, prescribed antihypertensive medicines were enrolled from cardiology and geriatric outpatient departments, after giving written informed consent. Patients having congestive heart failure (NYHA class III and IV) or other chronic conditions which could affect their ability to comprehend and respond to study questionnaire were excluded. The case report conditions which could affect their performance 28 patients because of concomitant diseases such as depression, rheumatoid arthritis and chronic obstructive pulmonary disease.

For data collected from first 20 participants, Cronbach’s alpha was 0.7, 0.8 and 0.7 for salt intake, appointment keeping and medication taking domain respectively. The construct validity of the scale was assessed using Principal Component Analysis (PCA) (Table 1). Bartlett’s test of sphericity showed normal distribution and appropriateness for factor analysis (p < 0.001). The mean inter-item correlation was 0.341 and Kaiser-Meyer-Olkin (KMO) coefficient was 0.591, suggesting correlation among coherent items. The Eigen value for individual 14 items was above 0.4 (Fig. 1). The disease burden of hypertension has been increasing over the last few decades. It could previously be controlled using single antihypertensive medicine. However, according to a survey conducted by the National Council of Patient Information and Education in 2014, most patients were taking at least two antihypertensives.

Increasing complexity of treatment regimen may influence compliance which is an important link between the prescribing and outcome. Compliance itself is also a complex issue for which more education in 2014, most patients were taking at least two antihypertensives.11 Compliance which is an important link between the prescribing and outcome. Compliance itself is also a complex issue for which more education in 2014, most patients were taking at least two antihypertensives.11

### 2.1 Statistical analysis

The scale reliability and construct validity were assessed using Cronbach’s alpha and Principal Component Analysis respectively. The data analysis was done using STATA 11.3. Pearson chi-square test, t test, one way ANOVA and correlation regression were used for parametric data and Ranksum test was used for comparison of treatment duration with antihypertensive medicine (non-parametric data). The results were considered significant if the p value was less than 0.05.

### 3. Results

Of the 502 patients screened, 452 met the inclusion criteria and completed the questionnaire (100% response). The study excluded 28 patients because of concomitant diseases such as depression, anxiety and Alzheimer’s which could affect their performance in a self-administered questionnaire, 17 patients refused to participate and 05 patients had incomplete records. The mean age of participants was 54.6 ± 13.7 years with 67.5% males most of whom attained higher secondary education. Among female participants (32.5%), majority had secondary education. The participants represented 14 states/Union territories. According to Kuppuswami’s Socio-Economic Status Scale, 2014, 9.3% participants were from upper class, 50.7% from upper middle, 29% from lower middle followed by 10.8% from upper lower and 0.2% from lower class. The median treatment duration with antihypertensive medicines was 3 years (IQR: 1–6 years). Concomitant diseases were noted in 32.5% patients of which most common were diabetes mellitus, rhema-ridor arthritis and chronic obstructive pulmonary disease.

### 4. Discussion

The disease burden of hypertension has been increasing over the last few decades. It could previously be controlled using single antihypertensive medicine. However, according to a survey conducted by the National Council of Patient Information and Education in 2014, most patients were taking at least two antihypertensives.11

| Item                                                                 | How often                                      | Score (Mean ± SD)      | Principal component analysis |
|---------------------------------------------------------------------|-----------------------------------------------|------------------------|-------------------------------|
| 1. Do you forget to take your HBP medicine?                         | 1.75 ± 0.70                                   | 0.634                  | 0.290                         | −0.143                        |
| 2. Do you decide not to take your HBP medicine?                     | 1.22 ± 0.49                                   | 0.581                  | 0.430                         | −0.110                        |
| 3. Do you eat salty food?                                            | 1.25 ± 0.50                                   | 0.490                  | −0.246                        | 0.176                         |
| 4. Do you shake salt, fondor, or aromat on your food before you eat it? | 1.47 ± 0.60                                   | 0.341                  | −0.513                        | 0.488                         |
| 5. Do you eat fast food?                                             | 1.59 ± 0.69                                   | 0.421                  | −0.419                        | 0.327                         |
| 6. Do you get the next appointment before you leave the clinic?      | 1.54 ± 0.87                                   | 0.337                  | 0.223                         | −0.298                        |
| 7. Do you miss scheduled appointments?                              | 1.28 ± 0.49                                   | 0.147                  | 0.355                         |                               |
| 8. Do you leave the dispensary without obtaining your prescribed pills? | 1.35 ± 0.66                                   | 0.222                  | −0.154                        | −0.175                        |
| 9. Do you run out of HBP pills?                                     | 1.41 ± 0.60                                   | 0.364                  | −0.245                        | −0.119                        |
| 10. Do you skip your HBP medicines 1–3 days before you go to the clinic? | 1.28 ± 0.49                                   | 0.122                  |                               |                               |
| 11. Do you miss taking your HBP pills when you feel better?          | 1.52 ± 0.65                                   | 0.443                  | −0.104                        | −0.170                        |
| 12. Do you miss taking your HBP pills when you feel sick?            | 1.23 ± 0.45                                   | 0.246                  | 0.497                         | 0.465                         |
| 13. Do you take someone else’s HBP pill?                            | 1.2 ± 0.42                                    | 0.255                  | 0.407                         | 0.435                         |
| 14. Do you miss taking your HBP pills when you care less?            | 1.66 ± 0.71                                   | 0.454                  | −0.301                        | −0.424                        |

HBP: High blood pressure.
participants of our study. There could be skewing at a tertiary care centre which may not be representative of other levels of healthcare. However, a Nigerian tertiary centre study also reported 61.2% compliance among hypertensive patients.18 There could be skewing at a tertiary care centre which may not be representative of other levels of healthcare.

Several questionnaires are available to assess compliance, of which Hill-bone scale is specifically validated for antihypertensive therapy.7 Hence, in the present study Hill-bone scale was assessed for suitability in Indian patients and percent compliance was correlated with the factors that might affect it. A study conducted in Namibian population showed positive internal consistency for the three domains, once they removed two out of fourteen questions.8 However the present study found good internal consistency with all the three domains of the questionnaire, as evidenced by the Cronbach’s alpha and PCA. The scale score, irrespective of the domains, was similar to previous studies from other parts of the world.

Age and gender are known factors affecting compliance.10 Shruthi et al had reported progressively poor compliance with increasing age.10 However more elderly patients were compliant in our study. The reasons were not explored in the study but could possibly be due to more concern for health than wealth. In addition, relatively higher education for males could be the reason of better compliance in males although compliance and education were not directly associated. The other, rather intangible factor could be more concern for the bread winner of the family in our patriarchal society. Similar gender predilection was also reported in the Namibian population.7

Awareness about the disease and treatment is likely to make patient more compliant and this was noted in the present study also.21 Treatment complexity is another aspect leading to poor compliance. More the number of medicines to be taken daily and more the adverse effects less is the compliance. This was also reported by a study done in hypertensive Nigerian patients.22 However, significant association was not found in our study between number of medicines and adverse effects with compliance. Lifestyle modification and blood pressure monitoring have also been associated with compliance.23 However this correlation was not established in the present study.

To conclude, compliance should routinely be assessed with respect to antihypertensive treatment. The Hill Bone high blood pressure compliance scale demonstrated domain specificity and good internal consistency in Indian population. However, its use for interventional studies assessing compliance should keep potential confounders in mind.

### Declaration of Competing Interest

All authors have none to declare.

### Acknowledgement

The authors thank Mr Vishwajeet Singh, PhD Scholar in Department of Biostatistics, AIIMS for his help with the statistics.

### References

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 Nov;3(11): e442.
2. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009 Oct 20;120(16):1598–1605. https://doi.org/10.1161/circulationaha.108.830299.
3. Doroszko A, Janus A, Szahidewicz-Krupska E, et al. Resistant hypertension. Adv Chin Exp Med. 2016 Jan-Feb;25(1):173–183. https://doi.org/10.17219/acem/35098.
4. Kim MT, Hill MN, Bone LR, et al. Development and testing of the hill-bone compliance to high blood pressure therapy scale. Prog Cardiovasc Nurs. 2008;15(3):90–96. https://doi.org/10.1111/j.1751-7117.2008.tb00211.x.
5. Mwene MD, Banda J, Andrews B, et al. Factors associated with poor medication adherence in hypertensive patients in Lusaka, Zambia. Med J Zambia. 2010;37(4):252–261. https://www.ajol.info/index.php/mjz/article/view/76432.
6. Nielsen JO, Shrestha AD, Neupane D, et al. Non-adherence to anti-hypertensive medication in low-and middle-income countries: a systematic review and meta-analysis of 92443 subjects. J Hum Hypertens. 2017 Jan;31(1):14–21. https://doi.org/10.1038/jhh.2016.33.
7. Lambert EV, Steyn K, Stender S, et al. Cross-cultural validation of the hill-bone compliance to high blood pressure therapy scale in a South African, primary healthcare setting. Ethn Dis. 2006;16(1):286–291. https://www.ncbi.nlm.nih.gov/pubmed/16590385.
8. Nashilongo MM, Singu B, Kalemeera F, et al. Assessing adherence to antihypertensive therapy in primary health care in Namibia: findings and implications. Cardiovasc Drugs Ther. 2017 Dec;31(5-6):565–578. https://doi.org/10.1007/s10557-017-6756-8.
9. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *JAMA*. 2002 Dec;288(23):2981–2997. https://doi.org/10.1001/jama.288.23.2981.

10. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: A comparison of six antihypertensive agents with placebo. *N Engl J Med*. 1993 Apr 1;328(13):914–921. https://doi.org/10.1056/nejm199304013281303.

11. Dezii CM. Medication noncompliance: what is the problem? *Manag Care*. 2000 Sep;9(9):7–12. https://www.ncbi.nlm.nih.gov/pubmed/11729418.

12. Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. *Front Pharmacol*. 2013 Jul 25;4:91. https://doi.org/10.3389/fphar.2013.00091.

13. Jin J, Sklar GE, Oh VM, et al. Factors affecting therapeutic compliance: a review from the patient’s perspective. *Therapeut Clin Risk Manag*. 2008 Feb;4(1):269–296. https://doi.org/10.2147/crm.v4i1.956.

14. Santhanakrishnan I, Lakshminarayanan S, Kar SS. Factors affecting compliance to management of diabetes in Urban Health Center of a tertiary care teaching hospital of south India. *J Nutr Sci Biol Med*. 2014 Jul;5(2):365–368. https://doi.org/10.4103/0979-9668.136185.

15. Venkatachalum J, Abraham SB, Singh Z, et al. Determinants of patient’s adherence to hypertension medications in a rural population of Kancheepuram District in Tamil Nadu, South India. *Ind J Community Med*. 2015;40(1):33–37. https://doi.org/10.4103/0970-0218.148267. Jan-Mar.

16. Katapadi PR, Bant DD. A comparative study on the adherence to antihypertensive medications in urban and rural areas of Hubballi. *Int J Community Med Public Health*. 2019 Mar;6(4):1791–1796. https://doi.org/10.18203/2394-6040.ijcpm20191408.

17. Khwaja M, Ansari MA, Mehnaz S. Compliance to antihypertensive medication: a cross-sectional study in Aligarh. *Int J Community Med Public Health*. 2017 Sep 22;4(10):3698–3704. https://doi.org/10.18203/2394-6040.ijcpm20174236.

18. Ayodapo AO, Monsudi KF, Omosanya OE, Elegbede OT. Family functioning and adherence to medication: a study of hypertensive in a tertiary hospital, South Western Nigeria. *J Health Res*. 2018;5(3):197. https://doi.org/10.4103/cjhr.cjhr_28_18.

19. Hadji P, Jacob L, Kostev K. Gender-and age-related treatment compliance in patients with osteoporosis in Germany. *Patient Prefer Adherence*. 2016 Nov 23;10:2379–2385. https://doi.org/10.2147/ppa.s118396.

20. Shrutti R, Jyothi R, Pundarikaksha HP, et al. A study of medication compliance in geriatric patients with chronic illnesses at a tertiary care hospital. *J Clin Diagn Res*. 2016 Dec;10(12):40–43. https://doi.org/10.7860/jcdr/2016/21908.9068.

21. Gupta M, Gupta DD. Impact of awareness about hypertension on compliance to antihypertensive medication. *Int J Basic Clin Pharmacol*. 2013 Apr 1;6(4):226. https://doi.org/10.3389/fphar.2013.00091.

22. Olowofela AO, Isah AO. A profile of adverse effects of antihypertensive medicines in a tertiary care clinic in Nigeria. *Ann Afr Med*. 2017 Jul-Sep;16(3):114–119. https://doi.org/10.4103/aam.aam_6_17.

23. Adisa R, Ilesanmi OA, Fakeye TO. Treatment adherence and blood pressure outcome among hypertensive out-patients in two tertiary hospitals in Sokoto, Northwestern Nigeria. *BMC Cardiovasc Disord*. 2018 Oct 19;18(1):194–204. https://doi.org/10.1186/s12872-018-0934-x.